Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumabderuxtecan, for treating EGFR-mutated non-small cell lung ...
Some results have been hidden because they may be inaccessible to you